Cerebro-rhino orbital mucormycosis: An update

Journal of Infection and Public Health

Volumn 5, Issue 2, 2012, Pages 116-126

  Wali, Upender ^a   Balkhair, Abdullah ^a   Al Mujaini, Abdullah ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Antifungal agents; Cerebral; Hyperbaric oxygen; Mucoromycosis; Orbital

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DEFERASIROX; PLACEBO; POSACONAZOLE;

CEREBRORHINOORBITAL MUCORMYCOSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HYPERBARIC OXYGEN; INFECTION RISK; IRON CHELATION; LABORATORY TEST; MUCORMYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; HUMANS; MUCORMYCOSIS; ORBITAL DISEASES; RHINITIS;

EID: 84860232245     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2012.01.003     Document Type: Review

References (60)

1. Mayer A.C. Verschimmelung (Mucedo) imlebenden Korper. Deutsches Arch Physiol 1815, 1:310-312.
2. Fürbinger P. Beobachtungen über Lungenmycose beim Menshen. Virchows Arch (Pathol Anat) 1876, 66:330-365.
3. Gregory J.E., Golden A., Haymaker W. Mucormycosis of the central nervous system. A report of three cases. Bull John Hopkins Hosp 1943, 73:405-419.
4. Harris J. Mucormycosis: report of a case. Pediatrics 1955, 16:857-867.
5. Baker R.D. Mucormycosis-a new disease. JAMA 1957, 163:805-808.
6. Spellberg B., Edwards J., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556-569.
7. Hibbett D.S., Binder M., Bischoff J.F., Blackwell M., Cannon P.F., Eriksson O.E., et al. A higher-level phylogenetic classification of the fungi. Mycol Res 2007, 111:509-547.
8. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
9. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46(June (12)):1813-1821.
10. Sugar A.M. Agents of mucormycosis and related species. Principals and practice of infectious diseases 1995, 2311-2321. Churchill Livingstone, New York. 4th ed. G.L. Mandell, J.E. Bennet, R. Dolin (Eds.).
11. Ibrahim A.S., Gebermariam T., Fu Y., Lin L., Husseiny M.I., French S.W., et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649-2657.
12. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., Chamilos G., Healy M., Perego C., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
13. Bagdade J.D., Nielson K., Root R., Bulger R. Host defense in diabetes mellitus: the feckless phagocyte during poor control and ketoacidosis. Diabetes 1970, 19:364-366.
14. Ferguson B.J., Mitchell T.G., Moon R., Camporesi E.M., Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988, 10:551-559.
15. Artis W.M., Fountain J.A., Delcher H.K., Jones H.E. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferring and iron availability. Diabetes 1982, 31:109-114.
16. Schwartz J.N., Donnelly E.H., Klintworth G.K. Ocular and orbital phycomycosis. Surv Ophthalmol 1977, 22:3-28.
17. Bergstrom L.V., Hemenway W.G., Barnhart R.A. Rhinocerebral and otologic mucormycosis. Ann otol Rhinol Latyngol 1970, 79:70-81.
18. Sundaram C. Rhinocerebral zygomycosis-a clinicopathological study. Neurology India 1998, 46:126-129.
19. Nampoory M.R., Khan Z.U., Johny K.V., Constandi J.N., Gupta R.K., Al-Muzairi I., et al. Invasive fungal infections in renal transplant patients. J Infect 1996, 33:95-101.
20. Wens R., Devriendt J., Collart F. Rhino-cerebral mucormycosis in hemodialysis patients treated with desferrioxamine: possible role of recent surgery as an additional risk factor. Nephrol Dial Transplant 1991, 9:656-658.
21. Cooter R.D., Lim I.S., Ellis D.H., Leitch I.O. Burn wound zygomycosis caused by Apophysomyces elegans. J Clin Microbiol 1990, 28:2151-2153.
22. Cocanour C.S., Miller-Crotchett P., Reed R.L. Mucormycosis in trauma patients. J Trauma 1992, 32:12-15.
23. Cuadrado L.M., Guerrero A., Asejo J.A. Cerebral mucormycosis in two cases of acquired immuno deficiency syndrome. Arch Neurol 1988, 45:109-111.
24. Abe F., Inaba H., Katoh T., Hotchi M. Effects of iron and desferroxiamine on rhizopus infection. Micopathologia 1987, 110:87-91.
25. Windus D.W., Stokes T.J., Julian B.A., Fenves A.Z. Fatal Rhizopus infections in hemodilalysis patients receiving deferoxamine. Ann Int Med 1987, 107:678-680.
26. Baker R.D. Mucormycosis in human infection with fungi, Actinomycetes and algae 1971, Springer-Verlag, New York.
27. Parfrey N.A. Improved diagnosis and prognosis of mucormycosis. Medicine 1968, 65:113-123.
28. Onerci M., Gursel B., Horsal S., Gülekon N., Gököz A. Rhino-cerebral mucormycosis with extension to the cavernous sinus: a case report. Rhinology 1991, 29:321-324.
29. Dannaoui E., Schwarz P., Slany M., Loeffler J., Jorde T.A., Estrella-Cuenca M. Molecular detection and identification of zygomycetes species from paraffinembedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol 2010, 48:2043-2046.
30. Hammond S.P., Bialek R., Milner D.A., Petschnigg E.M., Baden L.R., Marty F.M.J. Molecular methods to improve diagnosis and identification of mucormycosis. Clin Microbiol 2011, 49(June (6)):2151-2153. [Epub 2011 Apr 20].
31. Terk M.R., Underwood D.J., Zee C.S., Colletti P.M. MR imaging in rhino-cerebral and intracranial mucormycosis with CT and pathologic correlation. Magn Reson Imaging 1992, 10:81-87.
32. Diego A.H., Arthur B.D., Eleanor L.O., Shervin A., Lydia P.H. Imaging findings of rhinocerebral mucormycosis. Skull Base 2009, 19(2):117-125.
33. Van Burik J.A., Hare R.S., Solomon H.F., Corrado M.L., Kontoyiannis D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:61-65.
34. Spellberg B., Ibrahim A. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 2010, 12:423-429.
35. Spellberg B., Walsh T.J., Kontoyiannis D.P., Edwards J., Ibrahim A.S. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009, 48:1743-1751.
36. Gleissner B., Schilling A., Anagnostopolous I., Siehl I., Thiel E. Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma 2004, 45:1351-1360.
37. Singh N., Aguado J.M., Bonatti H., Forrest G., Gupta K.L., Safdar N., et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009, 200:1002-1011.
38. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297.
39. Torres H.A., Hachem R.Y., Chemaly R.F., Kontoyiannis D.P., Raad I.I. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005, 5:775-785.
40. Arikan S., Sancak B., Alp S., Hascelik G., McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008, 12:1-7.
41. Lass-Flörl C., Mayr A., Perkhofer S., Hintenberger G., Hausdorfer J., Speth C., et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008, 52:3637-3641.
42. Greenberg R.N., Mullane K., van Burik J.A., Raad I., Abzug M.J., Anstead G., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
43. Ullmann A.J., Cornely O.A., Burchardt A., Hachem R., Kontoyiannis D.P., Töpelt K., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006, 50:658-666.
44. Lekakis L.J., Lawson A., Prante J., Ribes J., Davis G.J., Monohan G., et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant 2009, 15:991-995.
45. Schlemmer F., Lagrange-Xelot M., Lacroix C., La Tour R., Socie G., Molina J.M. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2008, 42:551-552.
46. Kontoyiannis D.P., Lewis R.E. How I treat mucormycosis. Blood 2011, 118(Aug (5)):1216-1224. [Epub 2011 May 26]. Review: Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin Microbiol Infect 2009;5:87-92.
47. Reed C., Bryant R., Ibrahim A.S., Edwards J.E., Filler S.G., Goldberg R., et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364-371.
48. Abe F., Shibuya H., Tateyama M., Ommura Y., Azumi N., Kimura K. Mucormycosis in diabetic ketoacidosis. Role of unbound iron binding capacity of transferrin. Acta Pathol Jpn 1986, 36:1507-1512.
49. Reed C., Ibrahim A., Edwards J.E., Walot I., Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968-3969.
50. Spellberg B., Andes D., Perez M., Anglim A., Bonilla H., Mathisen G.E., et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009, 53:3122.
51. Spellberg B., Ibrahim A.S., Chin-Hong P.V., Kontoyiannis D.P., Morris M.I., Perfect J.R., et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2011, Sep 20 [Epub ahead of print].
52. Couch L., Theilen F., Mader J.T. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg 1988, 114:791-794.
53. Yohai R.A., Bullock J.D., Aziz A.A., Markert R.J. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994, 39:3-22.
54. Barratt D.M., Van Meter K., Asmar P., Nolan T., Trahan C., Garcia-Covarrubias L., et al. Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model. Antimicrob Agents Chemother 2001, 45:3601-3602.
55. Abzug M.J., Walsh T.J. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004, 23:769-773.
56. Slavin M.A., Kannan K., Buchanan M.R., Sasadeusz J., Roberts A.W. Successful allogeneic stem cell transplant after invasive pulmonary zygomycosis. Leuk Lymphoma 2002, 43:437-439.
57. Blitzer A., Lawson M., Meyers B.R., Biller H.F. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope 1980, 90:635-648.
58. Abedi E., Sismanis A., Choi K., Pastore P. Twenty five years' experience treating Cerebro-Rhino-Orbital Mucormycosis. Laryngoscope 1984, 94:1060-1062.
59. Ochi J.W., Harris J.P., Feldman J.I., Press G.A. Rhinocerebral mucormycosis: results of aggressive surgical debridement and amphotericin B. Laryngoscope 1988, 98:1339-1342.
60. Kohn R., Helper R. Management of limited rhino-orbital mucormycosis without exenteration. Ophthalmology 1985, 92:1440-1444.